
    
      Prucalopride, a highly selective 5-HT4 receptor agonist, accelerates gastrointestinal transit
      which may reduce severity of ileus. Furthermore, there is no report of serious cardiac and
      neurological side effects. We aim to evaluate the efficacy of prucalopride as a prokinetic of
      choice on paralytic ileus in critically ill patients.
    
  